The Cogstate Limited (ASX: CGS) share price ripped more than 78% higher in early trade after the company released its quarterly cash flow statement and business update. It has since been sold down and is currently trading 30.95% higher at 55 cents per share.
What did Cogstate announce?
The company’s report was highlighted by a record high in sales contracts, with Cogstate executing $8.4 million in clinical trial sales contract for the quarter ending 30 June 2020. As a result, the company has completed $46 million in sales contracts for the year, making FY20 its most successful financial year.
Cogstate expects the substantial increase in clinical trial sales contracts to result in increased revenue for the quarter. The company also reported a cash positive quarter, with cash reserves totalling $10.6 million, an increase of $3.3 million during the period.
In addition to its cash flow statement for the quarter, Cogstate also provided the market with a business update regarding its partnership with ERT. According to the update, Cogstate has entered into a preferred partnership with ERT, which is a global leader in clinical endpoint data collection. The partnership will see the company deliver cognitive assessments via ERT’s technology platform, providing Cogstate with the potential to significantly expand its distribution channel.
What does Cogstate do?
Cogstate is a neuroscience technology company that specialises in brain health assessments, with the aim of advancing development of new medicines and clinical insights. The company’s technologies allow for rapid and reliable computerised cognitive tests, which are designed to replace traditional costly and error-prone paper assessments.
The company’s clinical trial solutions provide quality assurance services that streamline the measurement of clinical outcomes, whilst also eliminating the need for duplicate hardware.
Foolish takeaway
The Cogstate share price was trading around 78% higher in early trade, hitting an intra-day high of 80 cents. Since then the company’s share price has been sold-down and is currently trading around 30% higher at 55 cents.
3 “Double Down” Stocks To Ride The Bull Market
Motley Fool resident tech stock expert Dr. Anirban Mahanti has stumbled upon three under-the-radar stock picks he believes could be some of the greatest discoveries of his investing career.
He’s so confident in their future prospects that he has issued “double down” buy alerts on each of these three stocks to members of his Motley Fool Extreme Opportunities stock picking service.
*Extreme Opportunities returns as of June 5th 2020
More reading
- DroneShield share price surges 25% on US Air Force contract
- 3 ASX growth shares that could be long term market beaters
- Buy and hold Cochlear and these ASX shares for strong long term returns
- Are ASX 200 shares about to take off on another bull run?
- What to do if your ASX shares hit a record high
Motley Fool contributor Nikhil Gangaram has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The post Why the Cogstate share price soared 78% higher today appeared first on Motley Fool Australia.
from Motley Fool Australia https://ift.tt/3jtTuPX
Leave a Reply